表紙
市場調查報告書
商品編碼
692904

Digital Landscape:乾癬性關節炎(PsA)

Digital Landscape: Psoriatic Arthritis

出版日期: | 出版商: GlobalData | 英文 150 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供美國及EUCAN各國(歐盟5國、加拿大)的製藥企業用數位環境(品牌網站,非品牌/疾病認知網站,行動應用程式,社群媒體)乾癬性關節炎患者及醫護人員為對象展開的配合措施相關的詳細調查,主要企業趨勢比較,網站訪問數和應用程式下載數等的資料分析,新的宣傳活動活動的尋找機會,形成數位健康的趨勢的評估,患者及醫生的線上利用實際狀態等相關資訊彙整。

對象企業

AbbVie,Novartis,Celgene,Janssen,Amgen,MSD,Merck,UCB,BMS,Pfizer,Eli Lilly,Sandoz,Mylan

目錄

  • 摘要整理
  • 近幾年趨勢
  • 形勢與分析
  • 美國:乾癬性關節炎患者為對象的配合措施
  • 美國:醫護人員為對象的配合措施
  • EUCAN各國:乾癬性關節炎患者為對象的配合措施
  • EUCAN各國:醫護人員為對象的配合措施
  • 調查手法
目錄
Product Code: GDHC040SP

"Digital Landscape: Psoriatic Arthritis", analyzes digital activities undertaken by pharma in support of therapies for active psoriatic arthritis (PsA)

The report includes digital activities directed towards patients and/or HCPs.

The geographic scope of the report is the United States, EUCAN (Canada and the 5EU countries - UK, Germany, France, Italy & Spain).

Key Highlights

  • US Patients: AbbVie offers the strongest support for PsA patients in the US, with activity across all channels; most activity in 2017 detected in the branded space following license extensions in PsA, and new advertising campaigns seen for Cosentyx and Enbrel in PsA, while Janssen launched a Remicade-branded counter-biosimilar campaign. Opportunity exists for a well-integrated unbranded campaign to support patients, linked to social media and a mobile app.
  • US HCPs: Good branded support available for US HCPs in PsA, but advertising focus is on other indications. A number of brand sites were updated with PsA content in 2017. Unbranded and mobile app landscapes are sparse, and opportunities may exist to develop or sponsor content with trusted non-pharma organizations. Social media activity is restricted to corporate accounts, with examples of HCP-specific accounts seen in other diseases.
  • EUCAN Patients: Good branded support is available for PsA patients in Germany, the UK, and Canada. Unbranded support is strongest from AbbVie, Novartis and Janssen, however no multi-country, local-language campaigns detected. PsA patients have access to a number of mobile apps, but many are branded or are multi-condition. UCB provides the only example of a PsA-specific mobile app in Europe
  • EUCAN HCPs: The EUCAN HCP landscape is underdeveloped, with little activity seen past branded. The unbranded and mobile app landscapes are particularly sparse, and partnerships with non-pharma organizations may offer more effective opportunities to engage with and support HCPs.
  • Companies Mentioned: AbbVie, Novartis, Celgene, Janssen, Amgen, MSD / Merck, UCB, BMS, Pfizer, Eli Lilly, Sandoz, Mylan.

Scope

  • This report analyzes digital activities undertaken by pharma in support of therapies for therapies for active psoriatic arthritis (PsA).
  • The report includes digital activities directed towards patients and/or HCPs, including branded websites, unbranded disease awareness initiatives, social media and mobile apps.
  • The report is based on analysis conducted by a combination of GlobalData's digital and disease-specific teams. It also includes analysis of data licensed from third parties e.g. website traffic, search engine optimization (SEO), digital display advertising, mobile app downloads, and social media interaction.
  • The geographic scope of the report is the United States, Canada and the 5EU (UK, Germany, France, Italy & Spain), with EUCAN used as an abbreviation for Europe and Canada throughout.
  • This report covers the research period from January - December 2017.

Reasons to buy

  • Our Digital Landscape report provides an analysis of pharma multichannel activity in the digital PsA space, and can assist our pharma clients derive value in a number of ways:
  • Competitive Intelligence: Track and compare key competitor activity across channels and identify key trends in PsA
  • Digital Strategy: Strengthen corporate digital excellence, learn from industry best practice, and identify opportunities for novel digital campaigns
  • Support new brand launch: See best practice examples of pre- and post-launch digital activities, ascertain must-have digital assets for patient and HCP engagement, and assess potential gaps and opportunities for pipeline brands
  • Business Development & Licensing: Assess topics and trends shaping digital health in PsA and beyond, and learn about key patient and physician online activities in PsA.

Table of Contents

  • Executive Summary
  • Recent Developments
  • Landscape & Analysis
  • US: Patient-directed Activities
  • US HCP-directed Activities
  • EUCAN Patient-directed Activities
  • EUCAN HCP-directed Activities
  • Methodology